Certified Hospice and Palliative Assistant (CHPNA) Practice Test 2025 - Free CHPNA Exam Practice Questions and Preparation Guide

Question: 1 / 400

What does methylnaltrexone inhibit in patients on opioids?

Urinary retention

Opioid-induced gastrointestinal slower motility

Methylnaltrexone is a medication specifically designed to treat opioid-induced gastrointestinal slowing, or reduced motility, in patients who are using opioids for pain management. Opioids often cause constipating effects by binding to opioid receptors in the gastrointestinal tract, which leads to decreased gut motility and the potential for constipation.

Methylnaltrexone works as a peripherally acting opioid receptor antagonist. It selectively blocks the action of opioids in the gut without affecting their pain-relieving effects in the central nervous system. By inhibiting this action at the gastrointestinal level, methylnaltrexone facilitates bowel movements and relieves the discomfort associated with constipation caused by opioid use.

The other options are not the primary effects of methylnaltrexone. For example, while it indirectly affects urinary retention linked to opioid use, it does not specifically inhibit this effect as its primary action. Methylnaltrexone does not alter the sensation of pain, since its action is targeted to the gastrointestinal system. Lastly, it does not have a role in inhibiting blood clot formation, which is unrelated to its function as an opioid antagonist. Thus, the main and correct role of methylnaltrexone is to alleviate opioid-induced

Get further explanation with Examzify DeepDiveBeta

The sensation of pain

Blood clot formation

Next Question

Report this question

Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy